BC Week In Review | Dec 21, 2009
Company News

Arpida, Evolva deal

Evolva and Arpida completed their previously announced reverse merger. The newco was renamed Evolva Holding S.A. (SIX:EVE) (see BioCentury, Sept. 14). Arpida Ltd. , Reinach, Switzerland   Evolva S.A. , Allschwil, Switzerland   Business: Infectious, Renal, Cardiovascular...
BC Week In Review | Dec 21, 2009
Financial News

Evolva financial update

Evolva raised CHF21 million ($20.4 million) in a second close of a series B round, bringing the total raised in the round to CHF49 million ($48 million). New investor Entrepreneurs Fund joined existing investors Novartis...
BC Extra | Dec 15, 2009
Financial News

Evolva raises $20.4 million, completes reverse merger

Evolva Holding S.A. (SIX:EVE) raised CHF21 million ($20.4 million) in a second close of a series B round and completed its previously announced merger with Arpida Ltd. The company (formerly Evolva S.A. ) raised a total...
BC Week In Review | Nov 9, 2009
Company News

Evolva management update

Evolva S.A. , Allschwil, Switzerland   Business: Chemistry   Hired: Jessica Mann as CMO  ...
BC Week In Review | Oct 26, 2009
Financial News

Evolva completes venture financing

Evolva S.A. , Allschwil, Switzerland   Business: Chemistry   Date completed: 10/22/09   Type: Venture financing   Raised: CHF28 million ($27.6 million)   Investors: Aravis Venture; Auriga Partners; Vinci Capital - Renaissance PME; Wellington Partners; BioMedInvest; Astellas...
BC Week In Review | Oct 26, 2009
Clinical News

iclaprim regulatory update

Arpida withdrew an MAA for IV iclaprim to treat complicated skin and soft tissue infections (cSSTIs) after receiving a negative opinion from EMEA's CHMP on the application. The company said the withdrawal will not affect...
BC Extra | Oct 24, 2009
Financial News

Evolva raises $27.6 million

Evolva S.A. (Allschwil, Switzerland) raised CHF28 million ($27.6 million) in a series B round co-led by existing investor Aravis and new investors Auriga Partners; Vinci Capital - Renaissance PME; and Wellington Partners. Other participants included new...
BioCentury | Sep 21, 2009
Finance

Swiss on a roll

The Swiss biotech space hotted up last week as two of its leading funds, run by HBM Partners, picked up more than $200 million in a couple of trade sale exits, while Evolva S.A. announced...
BC Week In Review | Sep 14, 2009
Company News

Arpida, Evolva deal

Evolva plans to raise funds in an equity financing and subsequently reverse-merge with Arpida in a stock deal. The companies said Evolva will conduct an equity financing prior to the deal's completion and that investors...
BioCentury | Sep 14, 2009
Finance

Ebb & Flow

Besides rejecting a $14.50 per share takeover bid from Biogen Idec Inc. (NASDAQ:BIIB) last week, Facet Biotech Corp. (NASDAQ:FACT) made a couple of other moves to strengthen its position. The board put a poison pill...
Items per page:
1 - 10 of 13
BC Week In Review | Dec 21, 2009
Company News

Arpida, Evolva deal

Evolva and Arpida completed their previously announced reverse merger. The newco was renamed Evolva Holding S.A. (SIX:EVE) (see BioCentury, Sept. 14). Arpida Ltd. , Reinach, Switzerland   Evolva S.A. , Allschwil, Switzerland   Business: Infectious, Renal, Cardiovascular...
BC Week In Review | Dec 21, 2009
Financial News

Evolva financial update

Evolva raised CHF21 million ($20.4 million) in a second close of a series B round, bringing the total raised in the round to CHF49 million ($48 million). New investor Entrepreneurs Fund joined existing investors Novartis...
BC Extra | Dec 15, 2009
Financial News

Evolva raises $20.4 million, completes reverse merger

Evolva Holding S.A. (SIX:EVE) raised CHF21 million ($20.4 million) in a second close of a series B round and completed its previously announced merger with Arpida Ltd. The company (formerly Evolva S.A. ) raised a total...
BC Week In Review | Nov 9, 2009
Company News

Evolva management update

Evolva S.A. , Allschwil, Switzerland   Business: Chemistry   Hired: Jessica Mann as CMO  ...
BC Week In Review | Oct 26, 2009
Financial News

Evolva completes venture financing

Evolva S.A. , Allschwil, Switzerland   Business: Chemistry   Date completed: 10/22/09   Type: Venture financing   Raised: CHF28 million ($27.6 million)   Investors: Aravis Venture; Auriga Partners; Vinci Capital - Renaissance PME; Wellington Partners; BioMedInvest; Astellas...
BC Week In Review | Oct 26, 2009
Clinical News

iclaprim regulatory update

Arpida withdrew an MAA for IV iclaprim to treat complicated skin and soft tissue infections (cSSTIs) after receiving a negative opinion from EMEA's CHMP on the application. The company said the withdrawal will not affect...
BC Extra | Oct 24, 2009
Financial News

Evolva raises $27.6 million

Evolva S.A. (Allschwil, Switzerland) raised CHF28 million ($27.6 million) in a series B round co-led by existing investor Aravis and new investors Auriga Partners; Vinci Capital - Renaissance PME; and Wellington Partners. Other participants included new...
BioCentury | Sep 21, 2009
Finance

Swiss on a roll

The Swiss biotech space hotted up last week as two of its leading funds, run by HBM Partners, picked up more than $200 million in a couple of trade sale exits, while Evolva S.A. announced...
BC Week In Review | Sep 14, 2009
Company News

Arpida, Evolva deal

Evolva plans to raise funds in an equity financing and subsequently reverse-merge with Arpida in a stock deal. The companies said Evolva will conduct an equity financing prior to the deal's completion and that investors...
BioCentury | Sep 14, 2009
Finance

Ebb & Flow

Besides rejecting a $14.50 per share takeover bid from Biogen Idec Inc. (NASDAQ:BIIB) last week, Facet Biotech Corp. (NASDAQ:FACT) made a couple of other moves to strengthen its position. The board put a poison pill...
Items per page:
1 - 10 of 13